Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496665 · ClinicalTrials.gov registry record · Phase 1
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00496665 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants.
The verdict
NCT00496665, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safety and tolerability of the combination of Zactima with metronomic chemotherapy. Zactima is an oral anti-angiogenesis drug, which means it fights cancer by cutting off a tumor's blood supply. Thus, the drug starves the tumor by preventing the delivery of nutrients and oxygen. Metronomic chemotherapy is low dose oral chemotherapy pills which are taken daily. Unlike traditional chemotherapy, metronomic chemotherapy is thought to fight cancer like Zactima, by cutting off the blood supply to tumors. Because the dose is very low, the side effects are generally mild and very different from those with higher dose chemotherapy given by vein.
Interventions
- DRUG Cyclophosphamide
- DRUG Methotrexate
- DRUG Vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496665
The ClinicalTrials.gov registry entry for NCT00496665 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00496665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496665 about?
NCT00496665 is a clinical study titled "ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer". The purpose of this research study is to determine the safety and tolerability of the combination of Zactima with metronomic chemotherapy. Zactima is an oral anti-angiogenesis drug, which means it fights cancer by cutting off a tumor's blood supply. Thus, the drug starves the tumor by preventing the...
What is the current status of trial NCT00496665?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00496665?
The interventions under investigation include: Cyclophosphamide (DRUG), Methotrexate (DRUG), Vandetanib (DRUG).
Who is sponsoring clinical trial NCT00496665?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.